Figure 1

Structure of Ba/F3-VEGFR2 cells. Ba/F3-VEGFR2 cells exhibit two critical receptors; the VEGFR2/mEpoR chimera (consisting of the extracellular domain of VEGFR2 fused to the transmembrane and cytoplasmic domain of mEpoR) and the mIL3 receptor (A). Ba/F3-VEGFR2 proliferate and survive on mIL3 or hVEGF. When grown in medium devoid of these growth factors the cells stop proliferating (B). Before start of treatment VEGF is able to bind VEGFR2 (C). Upon start of treatment with bevacizumab a new equilibrium arises of free VEGF, free bevacizumab and VEGF bound to bevacizumab (D).